If you or a loved one is in immediate crisis: call 988 (Suicide & Crisis Lifeline) or 1-800-662-HELP (SAMHSA National Helpline). This page is informational and not a replacement for medical advice. Decisions about medication for opioid use disorder require consultation with a qualified prescriber.
Vivitrol vs Suboxone for OUD
Compare Vivitrol (XR-naltrexone) and Suboxone (Buprenorphine/Naloxone) across 13 decision points — cost, evidence, named criteria for choosing each option.
- Free & confidential
- 24/7 availability
- Insurance verified in 5 min
- HIPAA-compliant
- No pressure, just answers
Other treatment comparisons
Side-by-side comparison (13 decision points)
| Factor | Vivitrol (XR-naltrexone) | Suboxone (Buprenorphine/Naloxone) |
|---|---|---|
| Drug class | Opioid antagonist (blocks receptors) | Partial opioid agonist + naloxone |
| FDA approval for OUD | 2010 | 2002 (film 2010) |
| Dosing | Monthly 380mg IM injection | Daily sublingual film/tablet (or monthly Sublocade) |
| Pre-induction abstinence required | 7-10 days opioid-free | 12-24 hours after last short-acting opioid |
| Withdrawal symptom relief | No (post-detox medication) | Yes (immediate) |
| Craving suppression | Blocks opioid reward | Directly suppresses craving |
| Overdose-mortality reduction (NIDA) | Effective when adherent | ~50% reduction (strongest evidence) |
| Real-world 6-month retention | ~60% | ~70% |
| Take-home / portable | No — clinical administration | Yes (Suboxone) / No (Sublocade) |
| Diversion risk | None (clinical injection only) | Moderate (take-home medication) |
| Cost (uninsured) | $1,500-$1,800 per dose | $30-$600/month (generic vs brand) |
| Liver monitoring | Required (hepatotoxicity warning) | Not required |
| Best for population | Post-residential, court-mandated, motivated | Any OUD severity needing immediate stabilization |
Pros and cons
Vivitrol (XR-naltrexone)
Pros
- No opioid in your body — appeals to people who don't want any opioid medication
- Monthly dosing — no daily decision burden
- Zero diversion risk
- No precipitated withdrawal risk during transitions
- No respiratory depression risk at all
- Good for court-ordered or monitored treatment (verifiable monthly visits)
Cons
- Requires 7-10 days complete opioid abstinence to start — high dropout barrier
- Doesn't treat withdrawal — must complete detox first
- Doesn't prevent overdose if patient relapses after lost tolerance
- Expensive ($1,500-$1,800/dose uninsured)
- Once injected, can't reverse for 30 days
- Weaker overdose-mortality reduction evidence than buprenorphine/methadone
Suboxone (Buprenorphine/Naloxone)
Pros
- Immediate withdrawal relief — start during active withdrawal
- Strongest overdose-mortality reduction evidence (~50% per NIDA)
- Can start within 12-24 hours of last use (vs Vivitrol's 7-10 days)
- Office-based prescribing (post-2023 X-waiver elimination)
- Direct craving suppression
- Multiple formulations: film, tablet, Sublocade monthly injection, Brixadi weekly
Cons
- Daily medication requires consistent adherence
- Diversion risk with take-home formulations
- Some pharmacies still refuse to stock despite legal protection
- Precipitated withdrawal risk during induction (especially fentanyl)
- Slow taper required if discontinuing (1-4 weeks)
- Stigma about "still being on opioids" — though clinically inaccurate
When to choose each option
Named decision criteria for matching your specific situation to the right option.
When to choose Vivitrol (XR-naltrexone)
Post-residential discharge transition
Vivitrol fits best for people transitioning out of residential treatment who have already completed detox + 30-90 days inpatient. The 7-10 day opioid-free requirement is automatically satisfied. The monthly injection provides post-discharge protection against impulse relapse during the high-risk first 90 days back in the community.
Court-ordered or monitored treatment
If treatment is court-ordered, employer-mandated, or monitored by probation, Vivitrol provides easy verification (documented monthly clinic visit). Compared to Suboxone (daily medication with diversion risk), the monthly injection model is structurally simpler for monitored treatment plans.
Strong preference against opioid medication
Some people — for personal, philosophical, or recovery-community reasons — strongly prefer no opioid medication of any kind. While "abstinence-only" recovery has worse mortality outcomes than MOUD, Vivitrol offers a middle path: not abstinence-only, but also not on an opioid agonist. For people who reject buprenorphine on these grounds, Vivitrol is the next-best MOUD option.
Adolescents and young adults
Vivitrol has stronger evidence base in adolescent and young-adult populations (under 25), where prefrontal cortex development affects daily decision-making. The monthly injection bypasses daily impulsivity — appropriate for college students, young adults transitioning to independence, or anyone whose executive function makes daily adherence harder.
When to choose Suboxone (Buprenorphine/Naloxone)
Active withdrawal needing immediate relief
Suboxone is the right choice for someone currently in opioid withdrawal who needs immediate relief. Start within 12-24 hours of last short-acting opioid use (heroin, fentanyl, prescription opioids). Within 30-60 minutes of first dose, withdrawal symptoms resolve and you're stabilized. Vivitrol, by contrast, can't be started until 7-10 days of complete opioid abstinence — most people in active withdrawal won't make it that long without relapsing.
Strongest mortality reduction evidence
If reducing overdose mortality is the primary clinical goal — and for fentanyl-era OUD, it should be — buprenorphine and methadone have substantially stronger evidence than naltrexone formulations. NIDA Research Reports consistently show MOUD agonists (buprenorphine, methadone) reduce overdose death by ~50%, while naltrexone's mortality data is weaker due to the lost-tolerance relapse risk.
Office-based access without OTP barrier
Suboxone is prescribed by any DEA-registered clinician (post-2023 X-waiver elimination) — primary care physicians, psychiatrists, addiction medicine specialists, even some nurse practitioners. This dramatically expands access compared to Vivitrol (requires clinical injection administration) or methadone (OTP-only).
Multiple delivery formats
Suboxone offers more flexibility than Vivitrol: standard sublingual film, generic buprenorphine tablets, Subutex (buprenorphine alone), Sublocade (monthly injection), Brixadi (weekly or monthly injection). If daily film doesn't fit lifestyle, Sublocade provides Vivitrol-like monthly dosing but with opioid agonism. This flexibility supports adherence across different patient profiles.
Cost & financial impact
Pricing ranges with cited sources (SAMHSA TIP, MEPS, AHRQ, KFF).
Vivitrol monthly costs
- Medicaid: $0-$50 per dose in most states
- Private insurance: $50-$300 copay per dose (varies by plan)
- Medicare Part B: 20% coinsurance after deductible (~$300/dose typical)
- Uninsured: $1,500-$1,800 per dose; Alkermes patient assistance available
- Annual total (12 doses): $0-$3,600 with insurance; $18,000-$21,600 uninsured
Suboxone monthly costs
- Medicaid generic buprenorphine: $0-$5 copay
- Private insurance generic: $5-$40/month
- Private insurance brand Suboxone film: $40-$150/month (Tier 3)
- Sublocade (monthly injection): $1,500-$1,800/dose, similar to Vivitrol pricing
- Uninsured generic via GoodRx: $30-$80/month
- Annual total: $0-$1,800 with insurance generic; $360-$960 uninsured generic
Insurance and assistance
Both medications are covered by Medicaid in all 50 states. Private insurance covers both per MHPAEA federal parity. Manufacturer assistance: VivitrolConnect for Vivitrol; Indivior patient assistance for Suboxone. State opioid response (SOR) grants fund MOUD access for uninsured in most states.
Cost-effectiveness reality: For someone paying out-of-pocket, generic Suboxone is roughly 20-50× cheaper annually than Vivitrol. Even with insurance, brand-name medications may have higher copays than generic alternatives.
Our verdict
Choose Vivitrol (XR-naltrexone) if...
you can complete 7-10 days opioid-free before starting, you want monthly dosing convenience, you're in early structured recovery (residential discharge), or you don't want any opioid medication
Learn more about Vivitrol (XR-naltrexone) →Choose Suboxone (Buprenorphine/Naloxone) if...
you need immediate withdrawal relief and craving suppression, daily medication is feasible, you can't complete the 7-10 day opioid-free induction barrier, or you want stronger overdose-mortality reduction evidence
Learn more about Suboxone (Buprenorphine/Naloxone) →Still not sure which is right for you?
The level of care is a clinical decision based on addiction severity, withdrawal risk, and your home situation — not just personal preference. A free, confidential 2-minute self-assessment can help you gauge severity before you call, and our team can verify your insurance and match you to the right level of care at no cost.
Frequently asked questions
Which is more effective for OUD?
Why can't I just start Vivitrol while still using opioids?
Can I switch from Suboxone to Vivitrol or vice versa?
Does Vivitrol prevent overdose?
How long should I stay on Vivitrol or Suboxone?
Does Vivitrol require liver monitoring?
Can I drink alcohol on these medications?
Will insurance cover both?
What about Sublocade as a Suboxone alternative?
Where can I find a Vivitrol or Suboxone prescriber?
Sources & references
- NIDA — Medications for Opioid Addiction — NIDA Research Report on MAT effectiveness
- SAMHSA TIP 63 — MOUD — Federal MOUD treatment guidelines
- ASAM Clinical Guideline — OUD — American Society of Addiction Medicine
- X-BOT Trial (Lee et al. 2018) — Naltrexone vs buprenorphine 24-week trial
- CDC — Overdose Prevention — CDC overdose prevention + MOUD
- 988 Suicide & Crisis Lifeline — 24/7 crisis support
- SAMHSA National Helpline — 1-800-662-HELP
Need help deciding?
Free, confidential guidance from licensed advisors to help you choose between Vivitrol (XR-naltrexone) and Suboxone (Buprenorphine/Naloxone).
